luspatercept,epoetin alfa
bms
['lusp', 'paradigm', 'ts,perio,i', 'mds']
our presents at #asco23 about a study he led showing luspatercept is the first and only therapy to demonstrate head-to-head superiority against esas, bringing a paradigm shift in the treatment of lr-mds-associated anemia. 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789